Drug Discovery App CS WP

81. The Value Of Engaging A Single CDMO For Comprehensive Biologics Services 5/16/2024

    By forging strategic partnerships with comprehensive CDMOs, see how emerging biopharma firms can navigate through early-phase development and ensure a smooth transition to clinical advancement.

82. Developing A Large-Scale Tangential Flow Filtration Process 5/13/2024

    Discover a process that can be modified to fit your downstream process and serves as a complete solution for concentration and diafiltration.

83. Review Of Applications And Processes In Fixed-Bed Bioreactors 5/6/2024

    Gain insights and guidelines for developing new processes in this review evaluating publications on the applications of single-use, scalable fixed-bed bioreactors for adherent cell culture processes.

84. Lentiviral Vector Production Using Single-Use Bioreactors 5/6/2024

    Here, we outline a scalable and robust upstream process developed for LVV production of HEK293T cells and demonstrate how to expand HEK293T suspension cells.

85. Expansion Of Specific Lymphocytes With A Xeno-Free, Serum-Free Medium 4/29/2024

    Explore the advantages of utilizing a xeno- and serum-free medium for the targeted expansion of cell subpopulations without the addition of serum.

86. Bulk Filling Of Drug Substance | Accurate Aliquoting 4/24/2024

    Bulk filling drug substances in traditional facilities is often a lengthy, manual process where operators are relied upon to adjust pump controls to achieve accurate filling. This method, spanning multiple shifts, increases process risk through errors that can compromise accuracy.

87. Evaluating CAR T-Cell Therapy Vascular Recruitment, Trafficking, And Killing 4/24/2024

    Learn about a more human-relevant platform that enables researchers to assess the trafficking and killing efficiency of immunotherapy as well as the proof-of-concept of immuno-oncology co-therapy.

88. Optimizing Human iPSC Aggregate And Organoid Production For Bioprinting 4/17/2024

    This study aimed to identify the optimal cell culture conditions to yield high cell density and maintain high cell viability with consistent aggregate morphology and pluripotency marker expression.

89. Evaluating On-Target/Off-Tumor Effects Of Cancer Immunotherapies 4/9/2024

    A promising class of engineered T-cell engaging bispecific antibodies (TCBs) is revolutionizing cancer treatment, but safety concerns persist. Organs-on-Chips offer a human-relevant solution.

90. Exploring Neuroinflammation, Neurodegeneration With A Brain Organ-Chip 4/9/2024

    Examine how Organ-on-a-Chip technology, accurately mimicking human neuroinflammation, offers promising human-relevant avenues for neurodegenerative disease research and therapeutic development.